• 400+
    Pharmaceutical Partners
  • 150+
    Biomarker Assays
  • 300+
    Method Validations
  • 40+
    CDx

Clinical Testing

Patient Testing for Precision Medicine

  • Pan solid tumor
    Meet the diverse demands from clinicians and patients, MEDx Translational Medicine (MEDx) has developed a series of solid tumor tests, including pan-cancer gene panel tests, single cancer gene panel assays, and immunohistochemistry (IHC).
  • Hematologic Malignancy
    Most recently, molecular diagnostic products using PCR and next-generation sequencing (NGS) have significantly improved the understanding of molecular mechanism of hematological malignancies, leading to the right choice of molecular targeting drugs for precision therapy for the individual patients in clinic.
  • Infectious Disease
    Infectious Disease

About MEDx

Translational Medicine

MEDx Translational Medicine Co., Ltd (simply MEDx) was founded in 2013, formerly known as QIAGEN (Suzhou) Translational Medicine Co., Ltd.Obtained with comprehensive technology platforms, high quality system, and strong IVD R&D experience, MEDx has become a leading innovative company in companion diagnostics and the total solution provider for precision medicine in China.


Taking advantage of the comprehensive translational platforms including genomics, proteomics, cytomics, and pathology, MEDx offers integrated solutions from biomarker discovery, target validation, molecular testing, and patient  stratification for drug clinical trials, to the IVD/CDx R&D and commercialization. With a world-class technical team and a rich IVD/CDx pipeline, MEDx collaborates with hundreds of world-renowned pharmaceutical companies.

view more >>

Events

Happy Chinese New Year
MEDx TMC | Happy Mid-Autumn Festival
MEDx Invite You: Medlab Asia & Asia Health on July 10th-12th, 2024

We are honored to invite you to participate in the Medlab Asia & Asia Health, which will take

MEDx TMC | Happy Father’s Day!
Dragon Boat Festival
Welcome to visit the MEDx Booth at Medlab Middle East 2024

Time:5-8 February, 2024Address:Dubai World Trade CentreMEDx Booth No: # Z2.H19We are honored

Meet MEDx at Medlab Middle East | Dubai 2024
On series |PIK3CA gene mutation and targeted therapy

Introduction The study of cancer has been extended from single genes to macrogenes, and from sing

AI could help improve early detection of interval breast cancers

A new study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center suggests tha

Findings support use of personalized medicine approach to treat soft tissue sarcomas

A recent study has demonstrated that a precision medicine approach improves treatment selection for

A new type of super-strong antibody could boost immune systems of cancer patients

C-S disulfide variants exhibit the same trend in agonistic activity and conformation in anti-hCD40 a

New insights into how cancer spreads prompt rethink of metastasis care

Metastatic tumor cells traveling in the bloodstream as clusters, shown here as a pair of cells, larg

Novel CAR-T therapy achieves positive results in a high proportion of patients with a refractory typ

Researchers from the Sant Pau Research Institute (IR Sant Pau), in collaboration with Sant Pau Hospi

New blood test detects tumor-derived cell-free RNA with high sensitivity

Somewhere in the body of a patient, a small clump of cells, growing undetected, has begun to form a

Tumor byproduct blocks immune cells from fighting cancer, offering new treatment target

A team of researchers from the University of Chicago, in collaboration with researchers from the Uni

Some lung cancer patients may experience durable disease control even after discontinuing immunother

A subset of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhi